Purple Biotech to Present at 2025 AACR Meeting

Ticker: PPBT · Form: 6-K · Filed: Mar 28, 2025 · CIK: 1614744

Sentiment: neutral

Topics: conference-presentation, biotech, cancer-research

TL;DR

Purple Biotech's cancer research posters accepted for AACR 2025 meeting.

AI Summary

On March 28, 2025, Purple Biotech Ltd. announced that three of its posters have been accepted for presentation at the 2025 American Association for Cancer Research (AACR) Meeting. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.

Why It Matters

The acceptance of posters at a major cancer research conference like AACR signifies potential scientific validation and interest in Purple Biotech's research, which could impact future development and investment.

Risk Assessment

Risk Level: low — This filing is an announcement of poster acceptances for a conference, which is standard corporate communication and does not involve significant financial or operational changes.

Key Players & Entities

FAQ

What is the main purpose of this 6-K filing?

The filing announces that Purple Biotech Ltd. has had three posters accepted for presentation at the 2025 American Association for Cancer Research Meeting.

When was this announcement made?

The press release announcing the poster acceptances was issued on March 28, 2025.

What is Purple Biotech Ltd.'s former name?

Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.

Where is Purple Biotech Ltd. located?

Purple Biotech Ltd. is located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.

What type of company is Purple Biotech Ltd.?

Purple Biotech Ltd. is classified under Pharmaceutical Preparations (SIC code 2834).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 28, 2025 regarding PURPLE BIOTECH LTD. (PPBT).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing